Plasma hepcidin in early-stage breast cancer patients: No relationship with interleukin-6, erythropoietin and erythroferrone

Chiara Maura Ciniselli, Maida De Bortoli, Elena Taverna, Luca Varinelli, Sara Pizzamiglio, Silvia Veneroni, Chiara Bonini, Rosaria Orlandi, Paolo Verderio, Italia Bongarzone

Research output: Contribution to journalArticle

Abstract

Objective: Hepcidin-25 production is stimulated by systemic inflammation, and it interferes with iron utilization, leading to anemia. This study aimed to investigate the relationships between the plasma levels of hepcidin, interleukin-6 (IL-6), erythropoietin (EPO) and erythroferrone (ERFE) in patients with benign breast disease or cancer. Methods: Plasma samples from a cohort of 131 patients (47 with benign breast disease and 84 with breast cancer) were subjected to the evaluation of hepcidin, IL-6, EPO and ERFE using SELDI-TOF-MS or immunoassays. Results: An elevated hepcidin was observed in malignant breast tumors compared to benign ones. No correlation was observed between hepcidin and IL-6, EPO or ERFE. Conclusion: Since the study included a cohort of patients (87%) with breast cancers smaller than 2 cm, these results may support our previous evidence about the potential role of hepcidin in breast cancer disease.

Original languageEnglish
Pages (from-to)695-701
Number of pages7
JournalExpert Review of Proteomics
Volume12
Issue number6
DOIs
Publication statusPublished - Nov 2 2015

Keywords

  • benign breast disease
  • BMP6
  • breast cancer
  • early diagnosis
  • erytroferrone
  • erytropoiesis
  • erytropoietin
  • hepcidin
  • IL-6
  • inflammation
  • iron metabolism

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry

Fingerprint Dive into the research topics of 'Plasma hepcidin in early-stage breast cancer patients: No relationship with interleukin-6, erythropoietin and erythroferrone'. Together they form a unique fingerprint.

  • Cite this